chronic cough – Medxy AI

Gabapentin for Cough in Idiopathic Pulmonary Fibrosis: Efficacy and Safety Insights from a Randomized Controlled Trial

By MedXY 09/01/2026

A randomized, double-blind, placebo-controlled trial demonstrates gabapentin's significant efficacy and acceptable safety for treating cough in IPF, supporting its clinical use amid limited alternatives.

Neurology news Respiratory

Brain Structure Changes in Chronic Cough: Insights from a Large-Scale Longitudinal Study

By MedXY 08/11/2026

This large-scale longitudinal study reveals that chronic cough is linked with widespread grey matter volume reductions and accelerated brain atrophy, highlighting potential neurostructural underpinnings of cough hypersensitivity.

Internal Medicine news Respiratory

Oral Nalbuphine Significantly Reduces Cough Frequency in Patients with Idiopathic Pulmonary Fibrosis: Results from the CORAL Trial

By MedXY 01/25/2026

The CORAL Phase 2b trial demonstrates that oral nalbuphine extended release significantly reduces objective cough frequency and improves patient-reported symptoms in idiopathic pulmonary fibrosis, addressing a critical unmet need for managing this debilitating and often refractory symptom.

$Camlipixant for Refractory Chronic Cough: Promising Phase 2b Trial Results and Clinical Implications$

Clinical Updates news Respiratory Specialties

Camlipixant for Refractory Chronic Cough: Promising Phase 2b Trial Results and Clinical Implications

By MedXY 09/17/2025

The SOOTHE phase 2b trial demonstrates that camlipixant, a P2X3 antagonist, significantly reduces cough frequency and improves quality of life in refractory chronic cough patients, with a favorable safety profile, supporting its potential as a new therapeutic option.